Dawn joined the company in 2010 and became a member of the HEOR Board in 2019, when the company was known as BresMed. Before joining the company, Dawn worked for a transport economics consultancy, after gaining an MMath degree. She completed an MSc in health economics and decision modelling after starting at the company. She has experience in a number of disease areas and project types, and currently specializes in oncology modelling (in immuno-oncology in particular), early product assessment, health technology assessment (HTA) strategy, complex decision problems, models with complex statistical needs, end-to-end modelling solutions using R/R-SHINY and anything else “a bit weird and wonderful”. Dawn takes an advisory role on projects, with occasional hands-on technical modelling. Her role as Chief Scientific Officer, HEOR focuses on achieving and maintaining our position at the leading edge of health economics and outcomes research, identifying trends within the industry and new types of work and methods for the company.